
Francesco Del Galdo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6476448/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	First pilot study of extracellular volume MRI measurement in peripheral muscle of systemic sclerosis patients suggests diffuse fibrosis. Rheumatology, 2022, 61, 1651-1657.	1.9	2
2	Nailfold Microvascular Imaging by Dynamic Optical Coherence Tomography in Systemic Sclerosis: A Case-Controlled Pilot Study. Journal of Investigative Dermatology, 2022, 142, 1050-1057.	0.7	10
3	Symptom experience of limited cutaneous systemic sclerosis from the Patients' perspective: A qualitative study✰,✰✰,â~,â~â~ Seminars in Arthritis and Rheumatism, 2022, 52, 151926.	3.4	12
4	Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis. Arthritis Research and Therapy, 2022, 24, 19.	3.5	8
5	Ultrasound and elastography in the assessment of skin involvement in systemic sclerosis: A systematic literature review focusing on validation and standardization – WSF Skin Ultrasound Group. Seminars in Arthritis and Rheumatism, 2022, 52, 151954.	3.4	14
6	Change in calcinosis over 1 year using the scleroderma clinical trials consortium radiologic scoring system for calcinosis of the hands in patients with systemic sclerosis. Seminars in Arthritis and Rheumatism, 2022, 53, 151980.	3.4	10
7	Induction of Pro-Fibrotic CLIC4 in Dermal Fibroblasts by TGF-β/Wnt3a Is Mediated by GLI2 Upregulation. Cells, 2022, 11, 530.	4.1	5
8	Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial. European Journal of Endocrinology, 2022, 186, 441-455.	3.7	12
9	Downregulation of Vascular Hemeoxygenase-1 Leads to Vasculopathy in Systemic Sclerosis. Frontiers in Physiology, 2022, 13, .	2.8	0
10	Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. Rheumatology, 2022, 62, 234-242.	1.9	13
11	The intracellular chloride channel 4 (CLIC4) activates systemic sclerosis fibroblasts. Rheumatology, 2021, 60, 4395-4400.	1.9	9
12	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. Journal of Scleroderma and Related Disorders, 2021, 6, 66-76.	1.7	12
13	Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SScAcohorts. Clinical Rheumatology, 2021, 40, 2277-2284.	2.2	11
14	Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis. Rheumatology, 2021, 60, 2934-2945.	1.9	18
15	UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis. Journal of Rheumatology, 2021, 48, 1422-1426.	2.0	4
16	Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma. Annals of the Rheumatic Diseases, 2021, 80, 920-929.	0.9	23
17	Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. International Journal of Molecular Sciences, 2021, 22, 2894.	4.1	9
18	The PREdictor of MAlnutrition in Systemic Sclerosis (PREMASS) Score: A Combined Index to Predict 12 Months Onset of Malnutrition in Systemic Sclerosis, Frontiers in Medicine, 2021, 8, 651748.	2.6	7

#	Article	IF	CITATIONS
19	P149 The intracellular chloride channel 4 (CLIC4) plays an important role in systemic sclerosis fibroblast activation. Rheumatology, 2021, 60, .	1.9	0
20	Sildenafil Counteracts the In Vitro Activation of CXCL-9, CXCL-10 and CXCL-11/CXCR3 Axis Induced by Reactive Oxygen Species in Scleroderma Fibroblasts. Biology, 2021, 10, 491.	2.8	7
21	Fecal incontinence and scleroderma: Pathogenesis and unmet needs. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101686.	3.3	0
22	Global gene expression analysis of systemic sclerosis myofibroblasts demonstrates a marked increase in the expression of multiple NBPF genes. Scientific Reports, 2021, 11, 20435.	3.3	1
23	Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers. RMD Open, 2021, 7, e001689.	3.8	11
24	Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence. Autoimmunity Reviews, 2021, 20, 102978.	5.8	17
25	Practical Approach to Malnutrition and Weight Loss in SSc. In Clinical Practice, 2021, , 243-254.	0.0	Ο
26	Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). Lancet Rheumatology, The, 2021, 3, e834-e843.	3.9	42
27	One year in review 2021: systemic sclerosis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 3-12.	0.8	1
28	One year in review 2021: systemic sclerosis. Clinical and Experimental Rheumatology, 2021, 39, 3-12.	0.8	25
29	SFRP4 Expression Is Linked to Immune-Driven Fibrotic Conditions, Correlates with Skin and Lung Fibrosis in SSc and a Potential EMT Biomarker. Journal of Clinical Medicine, 2021, 10, 5820.	2.4	10
30	Sildenafil improves the redox homeostasis and pro-inflammatory activation in systemic sclerosis fibroblasts exposed to reactive oxygen species. Free Radical Biology and Medicine, 2021, 177, S70.	2.9	0
31	Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study. Clinical Rheumatology, 2020, 39, 27-36.	2.2	18
32	Abnormal electrophysiological testing associates with future incidental significant arrhythmia in scleroderma. Rheumatology, 2020, 59, 899-900.	1.9	4
33	P150 Influence of patient reported arthritis activity in determining sHAQ, HAQ-DI and Cochin scores in systemic sclerosis. Rheumatology, 2020, 59, .	1.9	Ο
34	P163 Biosamples from at risk SSc patients show classic pathological signs of scleroderma: opportunity for a diagnosis of pre-clinical SSc. Rheumatology, 2020, 59, .	1.9	0
35	New lessons for an old problem: ASSET open-label extension. Lancet Rheumatology, The, 2020, 2, e726-e727.	3.9	0
36	The Phosphodiesterase Type 5 Inhibitor Sildenafil Improves DNA Stability and Redox Homeostasis in Systemic Sclerosis Fibroblasts Exposed to Reactive Oxygen Species. Antioxidants, 2020, 9, 786.	5.1	12

#	Article	IF	CITATIONS
37	Long non-coding RNA HOTAIR induces GLI2 expression through Notch signalling in systemic sclerosis dermal fibroblasts. Arthritis Research and Therapy, 2020, 22, 286.	3.5	27
38	Sildenafil Reduces Expression and Release of IL-6 and IL-8 Induced by Reactive Oxygen Species in Systemic Sclerosis Fibroblasts. International Journal of Molecular Sciences, 2020, 21, 3161.	4.1	24
39	Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials. Lancet Rheumatology, The, 2020, 2, e173-e184.	3.9	12
40	Digital ulcers: should debridement be a standard of care in systemic sclerosis?. Lancet Rheumatology, The, 2020, 2, e302-e307.	3.9	7
41	Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH. Annals of the Rheumatic Diseases, 2020, 79, 507-517.	0.9	60
42	The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatology, The, 2020, 2, e71-e83.	3.9	182
43	Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis. Advances in Therapy, 2020, 37, 2460-2476.	2.9	10
44	Biomarkers as an opportunity to stratify for outcome in systemic sclerosis. European Journal of Rheumatology, 2020, 7, 193-202.	0.6	9
45	A special European Journal of Rheumatology issue on systemic sclerosis: What and why?. European Journal of Rheumatology, 2020, 7, S137-S138.	0.6	0
46	A special European Journal of Rheumatology issue on systemic sclerosis: What and why?. European Journal of Rheumatology, 2020, 7, 137-138.	0.6	0
47	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Annals of the Rheumatic Diseases, 2019, 78, 1576-1582.	0.9	31
48	Incidental significant arrhythmia in scleroderma associates with cardiac magnetic resonance measure of fibrosis and hs-TnI and NT-proBNP. Rheumatology, 2019, 58, 1221-1226.	1.9	31
49	Metabolic control of BRISC–SHMT2 assembly regulates immune signalling. Nature, 2019, 570, 194-199.	27.8	51
50	228 A monoclonal antibody against BDCA-2 inhibits TLR-induced activation of human pDC in vitro and in vivo: a novel therapeutic target for systemic sclerosis. Rheumatology, 2019, 58, .	1.9	0
51	Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts. Scientific Reports, 2019, 9, 4589.	3.3	12
52	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	5.6	75
53	SAT0262â€MODIFIED ACR COMPOSITE RESPONSE INDEX IN SYSTEMIC SCLEROSIS SCORE SHOWS SENSITIVIT AND EXTERNAL VALIDATION TO MEASURE MAGNITUDE OF RESPONSE AT 12 MONTHS IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS. , 2019, , .	(0
54	AB0966â€PROPOSAL OF OUTCOME MEASURES TO BE USED ON A 12-MONTH OPEN LABEL DRUG TRIAL IN JUVENILE SYSTEMIC SCLEROSIS. RESULTS OF THE 3RD CONSENSUS MEETING IN HAMBURG DECEMBER 2018. , 2019, , .		0

#	Article	IF	CITATIONS
55	AB0653â€SERUM CARDIAC BIOMARKERS BUT NOT SUBCLINICAL CARDIOVASCULAR MAGNETIC RESONANCE ABNORMALITIES IN SYSTEMIC SCLEROSIS ASSOCIATE WITH THE DEVELOPMENT OF CARDIOVASCULAR EVENTS. , 2019, , .		0
56	SAT0254â€VASODILATOR THERAPY IN THE LONG TERM PREVENTION OF MYOCARDIAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM DESSCIPHER INCEPTION COHORT STUDY. , 2019, , .		0
57	FRI0315â€SERUM INTERFERON SCORE PREDICTS CLINICAL OUTCOME AT 12 MONTHS IN DIFFUSE CUTANEOU SYSTEMIC SCLEROSIS AS MEASURED BY GLOBAL RANKED COMPOSITE SCORE (GRCS) AND COMPOSITE RESPONSE INDEX IN SSC(CRISS)., 2019,,.	IS	1
58	Threeâ€dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis. Clinical and Experimental Dermatology, 2019, 44, 462-465.	1.3	16
59	Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review). Molecular Medicine Reports, 2019, 20, 1488-1498.	2.4	10
60	A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography. Arthritis and Rheumatology, 2018, 70, 903-911.	5.6	65
61	Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study. Annals of the Rheumatic Diseases, 2018, 77, 1032-1038.	0.9	14
62	Transforming Growth Factor β Activation Primes Canonical Wnt Signaling Through Downâ€Regulation of Axinâ€2. Arthritis and Rheumatology, 2018, 70, 932-942.	5.6	25
63	Scleroderma fibroblasts suppress angiogenesis via TGF-î²/caveolin-1 dependent secretion of pigment epithelium-derived factor. Annals of the Rheumatic Diseases, 2018, 77, 431-440.	0.9	26
64	Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. Rheumatology, 2018, 57, 441-450.	1.9	60
65	There is a need for new systemic sclerosis subset criteria. A content analytic approach. Scandinavian Journal of Rheumatology, 2018, 47, 62-70.	1.1	28
66	O15â€∫Implantable loop recorder in systemic sclerosis over three years confirms incidental significant arrhythmia and suggests CMR and cardiac biomarker association. Rheumatology, 2018, 57, .	1.9	0
67	209 Normalisation of the American College of Rheumatology provisional composite response index in systemic sclerosis numerator for baseline data offers a measure of magnitude of response: results from a real-life observational study. Rheumatology, 2018, 57, .	1.9	0
68	Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model. International Journal of Oncology, 2018, 54, 537-549.	3.3	12
69	O18 The PREdictor of MAlnutrition in Systemic Sclerosis (PREMASS) score: the first validated combined index predictive of future weight loss in systemic sclerosis. Rheumatology, 2018, 57, .	1.9	0
70	European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. Rheumatology, 2018, 58, 254-259.	1.9	11
71	Association of circulating CXCL10 and CXCL11 with systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 1845-1846.	0.9	34
72	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. Arthritis and Rheumatology, 2018, 70, 1829-1834.	5.6	15

#	Article	IF	CITATIONS
73	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Research and Therapy, 2018, 20, 17.	3.5	75
74	Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. Programme Grants for Applied Research, 2018, 6, 1-528.	1.0	3
75	Use of optical coherence tomography for the diagnosis of preclinical lesions of circumscribed palmar hypokeratosis. Clinical and Experimental Dermatology, 2017, 42, 192-195.	1.3	10
76	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.9	794
77	Chylous ascites in a patient with an overlap syndrome: a surprising response to rituximab. BMJ Case Reports, 2017, 2017, bcr-2017-222339.	0.5	3
78	Absence of Scleroderma pattern at nail fold capillaroscopy valuable in the exclusion of Scleroderma in unselected patients with Raynaud's Phenomenon. BMC Musculoskeletal Disorders, 2016, 17, 342.	1.9	18
79	Does high-dose extended course cyclophosphamide and methylprednisolone pulse therapy have a role in the management of systemic sclerosis-related interstitial lung disease?. Rheumatology, 2016, 55, 2273-2275.	1.9	2
80	The Prognostic Significance of the Hedgehog Signaling Pathway in Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, 116-127.	2.3	34
81	A preliminary study using virtual touch imaging and quantification for the assessment of skin stiffness in systemic sclerosis. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 137-141.	0.8	14
82	88â€Characterisation of Sub-clinical Primary Myocardial Disease in Systemic Sclerosis – Preliminary Findings from a Cardiac Magnetic Resonance Study. Heart, 2015, 101, A48.2-A49.	2.9	0
83	Collagenous Colitis in Systemic Sclerosis. Journal of Clinical Rheumatology, 2014, 20, 278-282.	0.9	7
84	Quantitating Skin Fibrosis: Innovative Strategies and Their Clinical Implications. Current Rheumatology Reports, 2014, 16, 404.	4.7	25
85	The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 420-427.	0.9	37
86	The search for the <i>perfect animal model</i> discloses the importance of biological targets for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 635-636.	0.9	8
87	Skin imaging in systemic sclerosis. European Journal of Rheumatology, 2014, 1, 111-116.	0.6	18
88	Acute retinal artery occlusion in systemic sclerosis: A rare manifestation of systemic sclerosis fibroproliferative vasculopathy. Seminars in Arthritis and Rheumatism, 2013, 43, 204-208.	3.4	11
89	Virtual skin biopsy by optical coherence tomography: the first quantitative imaging biomarker for scleroderma. Annals of the Rheumatic Diseases, 2013, 72, 1845-1851.	0.9	77
90	Genetic ablation of caveolin-2 sensitizes mice to bleomycin-induced injury. Cell Cycle, 2013, 12, 2248-2254.	2.6	10

#	Article	IF	CITATIONS
91	Potential Use of Optical Coherence Tomography and High-Frequency Ultrasound for the Assessment of Nail Disease in Psoriasis and Psoriatic Arthritis. Dermatology, 2013, 227, 45-51.	2.1	44
92	Hedgehog Dysfunction in Fibrosis: Insights in the Pathogenesis of Scleroderma. Biochemistry & Pharmacology: Open Access, 2013, 02, .	0.2	0
93	Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood, 2012, 120, 2909-2917.	1.4	53
94	Combined Inhibition of c-Abl and PDGF Receptors for Prevention and Treatment of Murine Sclerodermatous Chronic Graft-versus-Host Disease. American Journal of Pathology, 2012, 181, 1672-1680.	3.8	28
95	A role for caveolin-1 in desmoglein binding and desmosome dynamics. Oncogene, 2012, 31, 1636-1648.	5.9	62
96	EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. Annals of the Rheumatic Diseases, 2011, 70, 1178-1182.	0.9	30
97	Optical Coherence Tomography: A New Tool to Assess Nail Disease in Psoriasis?. Dermatology, 2011, 222, 311-313.	2.1	41
98	The Early Growth Response Gene Egr2 (Alias Krox20) Is a Novel Transcriptional Target of Transforming Growth Factor-β that Is Up-Regulated in Systemic Sclerosis and Mediates Profibrotic Responses. American Journal of Pathology, 2011, 178, 2077-2090.	3.8	86
99	Biomarkers in the Management of Scleroderma: An Update. Current Rheumatology Reports, 2011, 13, 4-12.	4.7	22
100	Caveolin-1: A new therapeutic target in tissue fibrosis and scleroderma?. Cell Cycle, 2011, 10, 3629-3629.	2.6	4
101	NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Annals of the Rheumatic Diseases, 2010, 69, 2024-2033.	0.9	39
102	Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Annals of the Rheumatic Diseases, 2010, 69, 2017-2023.	0.9	37
103	Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials?. Rheumatology, 2010, 49, 1069-1075.	1.9	15
104	Junctional adhesion molecule-A is abnormally expressed in diffuse cutaneous systemic sclerosis skin and mediates myeloid cell adhesion. Annals of the Rheumatic Diseases, 2010, 69, 249-254.	0.9	20
105	Proteomic Analysis Identification of a Pattern of Shared Alterations in the Secretome of Dermal Fibroblasts from Systemic Sclerosis and Nephrogenic Systemic Fibrosis. American Journal of Pathology, 2010, 177, 1638-1646.	3.8	23
106	Improvement of Severe Systemic Sclerosis-associated Gastric Antral Vascular Ectasia Following Immunosuppressive Treatment with Intravenous Cyclophosphamide. Journal of Rheumatology, 2009, 36, 1653-1656.	2.0	37
107	The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1. Rheumatology, 2009, 48, 734-740.	1.9	29
108	Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells. American Journal of Physiology - Renal Physiology, 2009, 297, G1206-G1213.	3.4	63

#	Article	IF	CITATIONS
109	Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis and Rheumatism, 2009, 60, 1508-1518.	6.7	78
110	S1244 Immunoglobulins (IgGs) from Systemic Sclerosis (SSC) Patients Attenuate M3 Muscarinic Receptor Activation in Rat Internal Anal Sphincter (IAS) Smooth Muscle Cells (SMC). Gastroenterology, 2009, 136, A-220.	1.3	0
111	Caveolin-1â^'/â^' Null Mammary Stromal Fibroblasts Share Characteristics with Human Breast Cancer-Associated Fibroblasts. American Journal of Pathology, 2009, 174, 746-761.	3.8	123
112	Decreased expression of caveolin 1 in patients with systemic sclerosis: Crucial role in the pathogenesis of tissue fibrosis. Arthritis and Rheumatism, 2008, 58, 2854-2865.	6.7	159
113	Caveolin-1, transforming growth factor-β receptor internalization, and the pathogenesis of systemic sclerosis. Current Opinion in Rheumatology, 2008, 20, 713-719.	4.3	118
114	T cells expressing allograft inflammatory factor 1 display increased chemotaxis and induce a profibrotic phenotype in normal fibroblasts in vitro. Arthritis and Rheumatism, 2007, 56, 3478-3488.	6.7	44
115	TSK2, A MOUSE MODEL FOR HUMAN SCLERODERMA: CUTANEOUS CYTOKINES AND IMMUNE CELL ACTIVATION. Journal of Clinical Rheumatology, 2006, 12, S35.	0.9	0
116	The role of allograft inflammatory factor 1 in systemic sclerosis. Current Opinion in Rheumatology, 2006, 18, 588-593.	4.3	11
117	Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin. Clinical and Experimental Immunology, 2006, 144, 169-176.	2.6	27
118	T cells and B cells in the pathogenesis of systemic sclerosis: Recent insights and therapeutic opportunities. Current Rheumatology Reports, 2006, 8, 123-130.	4.7	9
119	Expression of allograft inflammatory factor 1 in tissues from patients with systemic sclerosis and in vitro differential expression of its isoforms in response to transforming growth factor β. Arthritis and Rheumatism, 2006, 54, 2616-2625.	6.7	64
120	Patients With Acute Coronary Syndrome Show Oligoclonal T-Cell Recruitment Within Unstable Plaque. Circulation, 2006, 113, 640-646.	1.6	116
121	Human Naive CD4 T-Cell Clones Specific for HIV Envelope Persist for Years In Vivo in the Absence of Antigenic Challenge. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 132-139.	2.1	5
122	Cytotoxic Molecule mRNA Expression in Chronically Rejected Human Kidney Allografts. Transplantation Proceedings, 2005, 37, 2476-2478.	0.6	4
123	Adoptive transfer of allogeneic Epstein–Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boostsLMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Annals of Oncology, 2004, 15, 113-117.	1.2	79
124	Therapeutic Effectiveness of Recombinant Cancer Vaccines Is Associated with a Prevalent T-Cell Receptor α Usage by Melanoma-specific CD8+ T Lymphocytes. Cancer Research, 2004, 64, 8068-8076.	0.9	22
125	Human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1-phosphate. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11170-11175.	7.1	94
126	Identification of new Th peptides from the cytomegalovirus protein pp65 to design a peptide library for generation of CD4 T cell lines for cellular immunoreconstitution. International Immunology, 2004, 16, 635-642.	4.0	36

#	Article	IF	CITATIONS
127	Cytokine mRNA expression in chronically rejected human renal allografts. Clinical Transplantation, 2004, 18, 564-570.	1.6	17
128	Dendritic Cells Pulsed with Polyomavirus BK Antigen Induce Ex Vivo Polyoma BK Virus–Specific Cytotoxic T-Cell Lines in Seropositive Healthy Individuals and Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2003, 14, 3197-3204.	6.1	73
129	Preservation of clonal heterogeneity of the Pneumocystis carinii -specific CD4 T cell repertoire in HIV infected, asymptomatic individuals. Clinical and Experimental Immunology, 2002, 128, 155-162.	2.6	7
130	Analysis of the antigen specific T cell repertoires in HIV infection. Immunology Letters, 2001, 79, 85-91.	2.5	7
131	Agreement between physician evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS). Arthritis Care and Research, 0, , .	3.4	1